TP53 and diffuse large B-cell lymphoma: Likewise, in patients with r/r DLBCL and concurrent TP53 alterations, superior best response (P < 0.001, Supplemental Fig. 8a) and DOR (P = 0.039, Supplemental Fig. 8b), and trends for better PFS (P = 0.086, Supplemental Fig. 8c) and OS (P = 0.076, Supplemental Fig. 8d) were demonstrated when administered ASCT incorporating CAR19/22 T-cell cocktail infusion.